What is the assessment and plan for a 24‑year‑old male with normal glycemic control, mild lymphocytosis, isolated transaminitis (elevated alanine aminotransferase, mildly elevated aspartate aminotransferase), normal renal function, normal thyroid function, dyslipidemia (elevated low‑density lipoprotein cholesterol, low high‑density lipoprotein cholesterol, normal triglycerides), and negative sexually transmitted infection screening?

Assessment and Plan for a 24-Year-Old Male with Transaminitis, Dyslipidemia, and Mild Lymphocytosis

Elevated Liver Enzymes (Transaminitis)

Your patient's ALT of 100 U/L represents a moderate elevation (~3× the upper limit of normal for males), which warrants systematic evaluation but does not require urgent hepatology referral at this time. 1

Initial Diagnostic Approach

Complete the following laboratory work-up immediately:

• Viral hepatitis serologies (HBsAg, anti-HBc IgM, anti-HCV) to exclude chronic viral hepatitis, which commonly causes fluctuating transaminase elevations 1, 2
• Iron studies (serum ferritin and transferrin saturation) to screen for hereditary hemochromatosis; a transferrin saturation >45% is clinically significant 1, 2
• Fasting glucose or HbA1c and fasting lipid panel (already obtained) to assess metabolic syndrome components 1, 2
• Creatine kinase (CK) to exclude muscle injury as a source of transaminase elevation, particularly if the patient engages in intensive exercise 1
• Thyroid function tests to rule out thyroid disorders as a cause of transaminase elevations 1

Obtain abdominal ultrasound as the first-line imaging test; it has 84.8% sensitivity and 93.6% specificity for detecting moderate-to-severe hepatic steatosis and can identify biliary obstruction, focal lesions, and portal hypertension 1, 2

Risk Stratification

Calculate the FIB-4 score using age, ALT, AST, and platelet count to stratify risk for advanced fibrosis 1, 2:

• Score <1.3 indicates low risk (≥90% negative predictive value for advanced fibrosis)
• Score >2.67 indicates high risk requiring hepatology referral

Most Likely Diagnosis: Nonalcoholic Fatty Liver Disease (NAFLD)

Given the patient's dyslipidemia (elevated LDL, low HDL) and the AST:ALT ratio <1 (51:100), NAFLD is the most probable diagnosis 1, 2. This pattern is characteristic of NAFLD and distinguishes it from alcoholic liver disease, where the AST:ALT ratio is typically ≥2 1.

Lifestyle Modifications (Cornerstone of Treatment)

Implement aggressive lifestyle changes immediately 1, 3:

• Weight loss target: 7–10% body weight reduction through caloric restriction 1, 3
• Dietary pattern: Low-carbohydrate, low-fructose diet; limit saturated fat to <7% of calories and cholesterol to <200 mg/day 1, 3
• Physical activity: 150–300 minutes per week of moderate-intensity aerobic exercise (≥3 days/week) plus resistance training ≥2 days/week 1, 3

Alcohol Assessment

Obtain a detailed, quantitative alcohol history using validated tools such as AUDIT or AUDIT-C 1. Even moderate alcohol consumption (≥14–21 drinks/week in men) can cause liver enzyme elevations and should be addressed with complete abstinence 1.

Monitoring Strategy

Repeat liver enzymes (ALT, AST) in 2–4 weeks to establish a trend 1, 2:

• If values remain stable or improve, continue monitoring every 4–8 weeks until normalized
• If ALT increases to ≥3× baseline or ≥300 U/L (whichever comes first), intensify evaluation for alternative etiologies including drug-induced liver injury 1

Hepatology Referral Criteria

Refer to hepatology if any of the following occur 1, 2:

• ALT remains elevated for ≥6 months without identified cause
• ALT increases to >5× ULN (>235 U/L for males)
• Evidence of synthetic dysfunction (elevated INR, low albumin, thrombocytopenia)
• FIB-4 score >2.67

Critical Pitfall to Avoid

Do not assume that mild ALT elevation is benign without proper evaluation; even modest increases can reflect significant pathology, and ALT elevation ≥5× ULN is rare in NAFLD alone and usually indicates viral hepatitis, autoimmune hepatitis, or drug-induced liver injury 1.

---

Dyslipidemia

Initiate statin therapy immediately despite the mildly elevated ALT, as cardiovascular disease is the leading cause of death in patients with NAFLD and dyslipidemia, far outweighing liver-related mortality. 1

Statin Initiation and Safety

Start atorvastatin 10–20 mg daily 1, 4:

• Statins are safe and effective even when ALT is modestly elevated (up to 2× ULN) 1, 4
• The safety threshold for statin-associated liver enzyme elevation is ALT ≥3× ULN; an isolated ALT of ~2× ULN does not require withholding statin therapy 4
• Statins reduce cardiovascular mortality in NAFLD patients and should be used as first-line therapy for dyslipidemia 1

Baseline Assessment Before Starting Statin

Obtain baseline ALT, AST, and creatine kinase (CK) levels to create a reference for future monitoring 4.

Monitoring Strategy After Statin Initiation

Re-check ALT, AST, and lipid panel at 4 weeks after starting statin 4:

• If ALT remains <3× ULN and the patient is asymptomatic, continue statin and repeat labs in 8 weeks, then every 3 months thereafter 4
• If ALT rises to ≥3× ULN on follow-up testing, temporarily hold statin, repeat liver tests in 2 weeks, and consider restarting with close monitoring once values normalize 4
• If ALT ≥3× ULN together with bilirubin ≥2× ULN, stop statin immediately and evaluate urgently for other causes 1, 4

Lifestyle Modifications for Dyslipidemia

Implement heart-healthy dietary changes 5:

• Limit daily fat intake to ≤30% of calories, with <7% from saturated fat 5, 3
• Limit sodium intake to ≤1,500 mg per day 5
• Eat at least 3 oz of whole grains, 2 cups of fruit, and 3 cups of vegetables per day 5

Exercise regularly: 150 minutes per week of moderate-intensity aerobic activity 5

Lipid Goals

Target LDL <100 mg/dL and HDL >40 mg/dL 5. Recheck lipid panel in 3–6 months to assess response to statin therapy and lifestyle modifications 5.

Critical Pitfall to Avoid

Do not postpone statin initiation because of mild ALT elevation; delaying therapy increases cardiovascular risk, the primary mortality driver in NAFLD 1. Untreated cardiovascular disease, not liver failure, is the predominant threat to survival in this population 1.

---

Mild Lymphocytosis

The mild lymphocytosis is most likely reactive (e.g., recent viral illness) and does not require immediate intervention. 1

Monitoring Strategy

Repeat complete blood count (CBC) in 4–6 weeks 1:

• If lymphocytosis resolves, no further action is needed
• If lymphocytosis persists or worsens, or if other cytopenias develop, consider further evaluation for hematologic disorders

---

Glucose Control

The patient's A1c of 5.4% is normal and indicates excellent glycemic control. 5 No intervention is needed at this time, but continue annual screening given the presence of metabolic syndrome components 5.

---

Follow-Up Plan

Schedule follow-up in 4 weeks to review:

• Repeat liver enzymes (ALT, AST) and lipid panel after statin initiation 1, 4
• Results of viral hepatitis serologies, iron studies, thyroid function tests, and creatine kinase 1
• Abdominal ultrasound findings 1
• FIB-4 score calculation 1
• Repeat CBC to reassess lymphocytosis 1

Emphasize lifestyle counseling at every visit, focusing on weight loss, dietary modifications, exercise, and alcohol cessation 1, 3.